Founded in 2001, our group is a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in peptides and oligonucleotides. Our integrated service model is designed to support partners through the most critical phases of drug development, with a particular focus on late-phase development, large-scale manufacturing, and commercial production. From initial discovery to full commercialization, we provide the expertise and infrastructure to accelerate your peptide and oligonucleotide programs to success.